CLXT Stock Overview
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.30|
|52 Week High||US$5.42|
|52 Week Low||US$0.27|
|1 Month Change||-15.25%|
|3 Month Change||-76.74%|
|1 Year Change||-92.59%|
|3 Year Change||-97.60%|
|5 Year Change||n/a|
|Change since IPO||-97.33%|
Recent News & Updates
|CLXT||US Biotechs||US Market|
Return vs Industry: CLXT underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: CLXT underperformed the US Market which returned -18.5% over the past year.
|CLXT Average Weekly Movement||14.8%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CLXT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CLXT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally.
Calyxt Fundamentals Summary
|CLXT fundamental statistics|
Is CLXT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLXT income statement (TTM)|
|Cost of Revenue||US$21.81m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.58|
|Net Profit Margin||-114.68%|
How did CLXT perform over the long term?See historical performance and comparison
Is CLXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLXT?
Other financial metrics that can be useful for relative valuation.
|What is CLXT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CLXT's PS Ratio compare to its peers?
|CLXT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: CLXT is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (39.3x).
Price to Earnings Ratio vs Industry
How does CLXT's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: CLXT is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is CLXT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.6x|
|Fair PS Ratio||3.7x|
Price-To-Sales vs Fair Ratio: CLXT is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (3.7x).
Share Price vs Fair Value
What is the Fair Price of CLXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CLXT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CLXT's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLXT's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Calyxt forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLXT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLXT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLXT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLXT's revenue (40.9% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CLXT's revenue (40.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLXT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Calyxt performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLXT is currently unprofitable.
Growing Profit Margin: CLXT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLXT is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare CLXT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CLXT has a negative Return on Equity (-166.14%), as it is currently unprofitable.
Discover strong past performing companies
How is Calyxt's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CLXT's short term assets ($19.0M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: CLXT's short term assets ($19.0M) exceed its long term liabilities ($13.9M).
Debt to Equity History and Analysis
Debt Level: CLXT is debt free.
Reducing Debt: CLXT has no debt compared to 5 years ago when its debt to equity ratio was 21.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLXT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CLXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.3% each year
Discover healthy companies
What is Calyxt current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLXT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLXT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CLXT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Carr (52 yo)
Mr. Michael Allen Carr has been President and Chief Executive Officer of Calyxt, Inc. since July 27, 2021 and serves as its Director. Mr. Carr previously served as the Vice President M&A, Strategy, and Inn...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD2.53M) is above average for companies of similar size in the US market ($USD752.25K).
Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.
Experienced Management: CLXT's management team is considered experienced (3 years average tenure).
Experienced Board: CLXT's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15%.
Calyxt, Inc.'s employee growth, exchange listings and data sources
- Name: Calyxt, Inc.
- Ticker: CLXT
- Exchange: NasdaqGM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$12.830m
- Shares outstanding: 42.77m
- Website: https://calyxt.com
Number of Employees
- Calyxt, Inc.
- 2800 Mount Ridge Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.